Table 2. Efficacy and safety outcomes according to treatment groups.
| Low dose NOACs (n = 97) |
Common dose NOACs (n = 51) |
Warfarin (n = 145) |
P value | ||||
| No. of events | Event rate (No./100 patient-years) | No. of events | Event rate (No./100 patient-years) | No. of events | Event rate (No./100 patient-years) | ||
| Efficacy | |||||||
| Stroke or systemic embolism | 1 | 0.85 | 1 | 1.84 | 6 | 2.98 | 0.69 |
| Stroke | 1 | 0.85 | 1 | 1.84 | 5 | 2.47 | 0.83 |
| Systemic embolism | 0 | – | 0 | – | 1 | 0.49 | 0.88 |
| Safety | |||||||
| Major bleeding | 8 | 6.97 | 7 | 13.29 | 24 | 12.46 | 0.34 |
| Decrease in Hb ≥ 2 g/dL | 7 | 6.10 | 7 | 13.29 | 21 | 10.89 | 0.33 |
| Critical organ bleeding | 1 | 0.85 | 0 | – | 3 | 1.51 | 0.84 |
| Fatal bleeding | 1 | 0.85 | 0 | – | 2 | 0.99 | 0.97 |
P value between treatment groups was achieved for the overall follow-up duration by univariable Cox regression model. Hb: hemoglobin; NOACs: non-vitamin K antagonist oral anticoagulants.